$MIRA SEC Filings

Filed On	Filing
28 Oct 2026	8-K: Regulation FD Disclosure MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
22 Oct 2026	8-K: Regulation FD Disclosure MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
17 Sep 2026	8-K: Regulation FD Disclosure MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
16 Sep 2026	8-K: Submission of Matters to a Vote of Security Holders On September 11, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The record date for stockholders entitled to notice of the Annual Meeting was July 21, 2026 (the “Reco...
01 Sep 2026	8-K: Regulation FD Disclosure
12 Aug 2026	10-Q
06 Aug 2026	8-K: Regulation FD Disclosure
31 Jul 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
28 Jul 2026	Proxy statement: annual meeting
10 Jul 2026	8-K: Regulation FD Disclosure
06 Jul 2026	8-K: Regulation FD Disclosure
25 Jun 2026	8-K: Regulation FD Disclosure
17 Jun 2026	8-K: Regulation FD Disclosure
15 Jun 2026	Form 4: Whalen Matthew Pratt, Director Granted 50,000 Stock Options (right to buy)
15 Jun 2026	Form 4: Del Giudice Matthew Paul, Director Granted 50,000 Stock Options (right to buy)
15 Jun 2026	Form 4: MacPherson Edward Clouston, Director Granted 50,000 Stock Options (right to buy)
15 Jun 2026	Form 4: Shekhat Denil Nanji, Director Granted 50,000 Stock Options (right to buy)
09 Jun 2026	Form 3: Mushak Andriy, Chief Financial Officer No securities owned
08 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation
04 Jun 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Comments